Tags

Type your tag names separated by a space and hit enter

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
Curr Opin Mol Ther 2010; 12(6):770-9CO

Abstract

Mogamulizumab (KW-0761; AMG-761), under development by Kyowa Hakko Kirin and Amgen, is a defucosylated humanized IgG1 mAb against C-C chemokine receptor 4 (CCR4) for the potential intravenous treatment of T-cell lymphomas and asthma. Chemokines and their receptors are signaling molecules constitutively responsible for lymphocyte and neutrophil chemotaxis, which can also be involved in pathogenic mechanisms of various diseases. In particular, CCR4 has been demonstrated to play a major role in adult T-cell leukemia/lymphoma (ATL), in which it is a marker of poor prognosis. Consequently, CCR4 blockade might have therapeutic potential in treating ATL, a disease that is most often aggressive in course, and for which existing therapies are not always effective. Mogamulizumab reduced tumor load via enhanced antibody-dependent cell cytotoxicity in preclinical studies and demonstrated promising efficacy in early clinical trials in patients with ATL. In addition, CCR4 also has a role in maintaining T-helper cell type 2 airways inflammation in asthma, and Amgen have acquired the rights to develop mogamulizumab for this indication and other non-oncology indications; however, at the time of publication, no data were available from Amgen's investigations. This is a review on the potential use of mogamulizumab for the treatment of T-cell lymphomas and asthma, with specific emphasis on the treatment of ATL.

Authors+Show Affiliations

University of Medicine and Pharmacy, Gr. T. Popa Iasi, Faculty of Medicine, Department of Medicine II - Pulmonary Disease, Pulmonary Disease University Hospital, 30 Dr I Cihac Street, Iasi 700115, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21154168

Citation

Antoniu, Sabina A.. "Mogamulizumab, a Humanized mAb Against C-C Chemokine Receptor 4 for the Potential Treatment of T-cell Lymphomas and Asthma." Current Opinion in Molecular Therapeutics, vol. 12, no. 6, 2010, pp. 770-9.
Antoniu SA. Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010;12(6):770-9.
Antoniu, S. A. (2010). Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Current Opinion in Molecular Therapeutics, 12(6), pp. 770-9.
Antoniu SA. Mogamulizumab, a Humanized mAb Against C-C Chemokine Receptor 4 for the Potential Treatment of T-cell Lymphomas and Asthma. Curr Opin Mol Ther. 2010;12(6):770-9. PubMed PMID: 21154168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. A1 - Antoniu,Sabina A, PY - 2010/12/15/entrez PY - 2010/12/15/pubmed PY - 2011/5/20/medline SP - 770 EP - 9 JF - Current opinion in molecular therapeutics JO - Curr. Opin. Mol. Ther. VL - 12 IS - 6 N2 - Mogamulizumab (KW-0761; AMG-761), under development by Kyowa Hakko Kirin and Amgen, is a defucosylated humanized IgG1 mAb against C-C chemokine receptor 4 (CCR4) for the potential intravenous treatment of T-cell lymphomas and asthma. Chemokines and their receptors are signaling molecules constitutively responsible for lymphocyte and neutrophil chemotaxis, which can also be involved in pathogenic mechanisms of various diseases. In particular, CCR4 has been demonstrated to play a major role in adult T-cell leukemia/lymphoma (ATL), in which it is a marker of poor prognosis. Consequently, CCR4 blockade might have therapeutic potential in treating ATL, a disease that is most often aggressive in course, and for which existing therapies are not always effective. Mogamulizumab reduced tumor load via enhanced antibody-dependent cell cytotoxicity in preclinical studies and demonstrated promising efficacy in early clinical trials in patients with ATL. In addition, CCR4 also has a role in maintaining T-helper cell type 2 airways inflammation in asthma, and Amgen have acquired the rights to develop mogamulizumab for this indication and other non-oncology indications; however, at the time of publication, no data were available from Amgen's investigations. This is a review on the potential use of mogamulizumab for the treatment of T-cell lymphomas and asthma, with specific emphasis on the treatment of ATL. SN - 2040-3445 UR - https://www.unboundmedicine.com/medline/citation/21154168/Mogamulizumab,_a_humanized_mAb_against_C-C_chemokine_receptor_4_for_the_potential_treatment_of_T-cell_lymphomas_and_asthma L2 - http://www.diseaseinfosearch.org/result/633 DB - PRIME DP - Unbound Medicine ER -